Skip to main content

Prous Institute moves to the PCB and expands its computational chemistry staff

By 17 de November de 2009November 18th, 2020No Comments
< Back to news

Prous Institute moves to the PCB and expands its computational chemistry staff

, a Catalan company dedicated to the discovery of drugs via computational techniques and experimental studies in the areas of cancer, diabetes and Alzheimer's disease, has moved its head offices and its computational chemistry group to new premises at the Barcelona Science Park (PCB), where its organic synthesis and pharmacology laboratories were already located.

The midterm objective of the company, as stated by its Business Development director, Xavier Mensa, is to expand its current 20-member staff in order to develop new computational chemistry projects and give support to the imminent agreement for the co-agreement of new predictive technologies with the Food and Drug Administration (FDA).

Prous Institute was created as a spin-off in the year 2000, by the hand of Dr. Josep R. Prous with the aim of applying the knowledge acquired in the world of medical and scientific publications to the world of research. Prous Institute is a private company owned by the Prous family and receives financial support from the CDTI, CIDEM and the Ministry of Science and Innovation.

Owing it to its technologies, Prous Institute carries out a dual business and complementary activity: on the one hand, it devotes part of its R&D activity to the discovery and development of new drugs for out-licensing projects and, on the other, it develops and distributes its chemoinformatic technologies, called i-drug solutions to the pharmaceutical industry, regulatory agencies and the academic world internationally.